Shares of Nevro Corp (NYSE:NVRO) have been assigned a consensus rating of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $99.71.
A number of analysts recently commented on the stock. Zacks Investment Research raised shares of Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Canaccord Genuity decreased their price objective on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. BidaskClub downgraded shares of Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. Northland Securities reissued a “buy” rating and set a $96.00 price objective on shares of Nevro in a report on Tuesday, November 7th. Finally, Leerink Swann reissued an “outperform” rating and set a $110.00 price objective (up previously from $105.00) on shares of Nevro in a report on Tuesday, November 7th.
Shares of Nevro (NVRO) opened at $75.56 on Tuesday. The company has a market cap of $2,232.19, a PE ratio of -52.11 and a beta of -0.59. Nevro has a fifty-two week low of $65.00 and a fifty-two week high of $99.63. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.